ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating

Click to view original post